Alert: Major Price Decline (10/8/19)-Nektar Therapeutics (NASDAQ: NKTR).


Nektar Therapeutics (NASDAQ: NKTR) stock closed at $16.18 on 10/8/19 after a major decline of -13.3%. Moreover, this decline was accompanied by above average trading volume at 127% of normal. The stock has been extremely weak relative to the market over the last nine months and has declined -11.2% during the last week.


Current PriceTarget Research Rating

NKTR is expected to continue to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.

Nektar Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Nektar Therapeutics has a poor Appreciation Score of 22 and a very low Power Rating of 12, and the Lowest Value Trend Rating results.

Rating Review

In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.

About John Lafferty 58358 Articles
During his career, John has developed valuation and stock rating methodologies, managed institutional portfolios and mutual funds, and provided equity research to institutional investors on thousands of companies. He has been Director of Research at PTR since its inception in 2004.

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.